 |
|
|
| |
Switching to Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination (DTG/ABC/3TC FDC) from a PI, INI or NNRTI Based Regimen
Maintains HIV Suppression at 48 Weeks
|
| |
| |
Reported by Jules Levin
Durban 2016 July 18-22
J Lake,1 B Trottier,2 J Garcia-Diaz,3 H Edelstein,4 P Kumar,5 UF Bredeek,6
M Loutfy,7 C Brennan,8 J Koteff,8 B Wynne,9 J Hopking,10 M Aboud11
1University of California, Los Angeles, CA, USA; 2Clinique Médicale l‘Actuel, Montreal, QC, Canada; 3Ochsner Clinic Foundation, New Orleans, LA, USA; 4Highland Hospital, Alameda Health System, Oakland, CA, USA; 5Georgetown University, Washington, DC, USA; 6Metropolis Medical, San Francisco, CA, USA; 7Maple Leaf Research, Toronto, Ontario, Canada; 8ViiV Healthcare, Research Triangle Park, NC, USA; 9ViiV Healthcare, Collegeville, PA, USA; 10GlaxoSmithKline, London, United Kingdom; 11ViiV Healthcare, London, United Kingdom
|
| |
|
|
|
|
|
